Salil Trehan, MD
Internal Medicine · Amarillo, TXNPI 1194766121
Payments from drug & device makers
Across 218 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$520
- AstraZeneca$436
- Pfizer$310
- Johnson & Johnson$310
- GSK$299
- Amgen$278
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,19798%
- Education$1012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $520 |
| AstraZeneca | 22 | $436 |
| Pfizer | 15 | $310 |
| Johnson & Johnson | 15 | $310 |
| GSK | 16 | $299 |
| Amgen | 16 | $278 |
| AbbVie(2 entities) | 11 | $216 |
| Phathom Pharmaceuticals, Inc. | 10 | $186 |
| Astellas Pharma US Inc | 4 | $161 |
| Dexcom, Inc. | 3 | $156 |
| Lilly USA, LLC | 8 | $151 |
| Novartis | 8 | $137 |
| Kowa Pharmaceuticals America, Inc. | 9 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $134 |
| Radius Health, Inc. | 7 | $120 |
| Merck | 6 | $88 |
| Sanofi | 1 | $86 |
| Bayer | 4 | $80 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Boehringer Ingelheim | 2 | $38 |
| Eisai Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Biogen | 2 | $27 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Abbott | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Sumitomo Pharma America, Inc. | 2 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,298 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 209 | $250,221 |
| MounjaroTirzepatide | 162 | $225,696 |
| OzempicSemaglutide | 112 | $189,729 |
| EliquisApixaban | 109 | $126,598 |
| JardianceEmpagliflozin | 97 | $117,614 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $98,656 |
| XareltoRivaroxaban | 51 | $64,352 |
| TymlosAbaloparatide | 15 | $51,259 |
| LinzessLinaclotide | 44 | $50,974 |
| TrulicityDulaglutide | 26 | $50,437 |
| MyrbetriqMirabegron | 58 | $48,490 |
| EntrestoSacubitril/Valsartan | 32 | $46,239 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,064 | $40,030 |
| Repatha SureclickEvolocumab | 34 | $39,551 |
| ProliaDenosumab | 21 | $35,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $151 | $276,132188 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $436 | $275,711231 claims |
| Novo NordiskOzempic | $520 | $189,729112 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $310 | $151,976138 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $299 | $132,193109 claims |
| Boehringer IngelheimJardiance | $38 | $117,61497 claims |
| Johnson & JohnsonXarelto | $310 | $64,35251 claims |
| AbbVieLinzess, Restasis | $216 | $58,46956 claims |
| MerckJanuvia, Janumet | $88 | $55,81553 claims |
| Radius Health, Inc.Tymlos | $120 | $51,25915 claims |
| Astellas Pharma US IncMyrbetriq | $161 | $48,49058 claims |
| NovartisEntresto | $137 | $46,23932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Amarillo
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.